NIKKEI 225
27,493.33 +166.22 (+0.61%) HANG SENG
21,842.33 -227.40 (-1.03%) CRUDE OIL
79.07 +0.20 (+0.25%) GOLD FUTURES
1,942.70 -2.60 (-0.13%) DOW
34,086.04 +368.95 (+1.09%) BTC-GBP
18,761.93 +108.58 (+0.58%)
Advanced Oncotherapy plc (AVO.L)
| Previous close | 10.50 |
| Open | 0.00 |
| Bid | 10.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 568,050 |
| Market cap | 45.161M |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -9.80 |
| Earnings date | 30 Sept 2022 - 03 Oct 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 166.00 |
- EQS Group
Hardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date
Hardman & Co Research Hardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date 27-Jan-2023 / 16:53 GMT/BSTAnalyst interview | Life SciencesQ&A on Advanced Oncotherapy (AVO) | Current EV significantly below cumulative investment to date Advanced Oncotherapy (AVO) was the topic of conversation when Dr Martin Hall joined DirectorsTalk.Martin updates us on some of the recent developments at the company, explains why the share price is lan
- EQS Group
Hardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
Hardman & Co ResearchHardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV 17-Jan-2023 / 15:10 GMT/BSTHardman & Co Research on Advanced Oncotherapy: Understanding the significance of 230MeV AVO’s goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury (UK) has been completed and demonstrated to
- Simply Wall St.
Independent Non-Executive Director Michael Bradfield Just Bought 6.4% More Shares In Advanced Oncotherapy plc (LON:AVO)
Even if it's not a huge purchase, we think it was good to see that Michael Bradfield, the Independent Non-Executive...
